Home › Therapeutic areas › Neurology › Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (13 companies)
Companies with an active program in Amyotrophic Lateral Sclerosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | 5 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | 6 |
| CRVO | CervoMed | Neurology Rare | 1 | Phase 2 | 4 |
| CLNN | Clene | Neurology Rare | 1 | Phase 3 | 5 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | 1 | Phase 2 | 3 |
| INSM | Insmed | CardiovascularImmunology+2 Rare | 1 | Approved | 17 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 3 | Approved | 29 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 1 | Phase 2 | 16 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 1 | Phase 2 | 3 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 1 | NDA Submitted | 6 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 1 | Phase 1 | 4 |
| PMN | ProMIS Neurosciences | Neurology Rare | 1 | Phase 1 | 6 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 2 | Phase 1 | 9 |
No companies match.